Along the same line, anti-glutamate drugs were shown to reduce the death of SCA2- and SCA3-iPSCs-derived neurons [87], further indicating that glutamate-associated pathways are very promising drug targets across the variegated spectrum of ataxias. The gene discussed is ATXN3; the disease is cerebellar ataxia.